What Ariel Precision Medicine does

Ariel Precision Medicine is a Pittsburgh-based, Pennsylvania-incorporated precision medicine company founded in 2014 that has built a clinical decision support platform centered on its proprietary ADVANCE Data Engine. The platform integrates multi-source inputs—including EHR/EMR records, genomic profiles, lab results, imaging, and peer-reviewed scientific literature—and processes them through a four-stage pipeline (Data Ingestion & Validation → Feature Interaction & Analysis → AI Model Inference & Correlation → Report Synthesis & Delivery) using traditional machine learning and equation-based modeling rather than generative LLMs, in order to mitigate hallucination risk. Output is delivered as peer-reviewed clinical reports with insights hyperlinked to PubMed PMIDs, accessed through Physician, Medical Professional, and Patient portals. The company serves hospital systems and specialty clinics managing complex disease cases, and the platform is positioned as a living genetic and clinical intelligence layer that updates with every new symptom or lab result, building a compounding proprietary knowledge graph.

Beyond diagnostics, Ariel maintains a therapeutic development pipeline anchored by APM-176, an oral small molecule targeting CFTR function that has completed Phase 1 (N=88) and is Phase 2 ready for respiratory indications including chronic rhinosinusitis, bronchiectasis, asthma, and COPD. A preclinical intra-nasal formulation of APM-176 is also in development for digestive and metabolic diseases. Revenue is generated through three streams: recurring clinical diagnostic report services to healthcare providers, professional services partnerships with pharmaceutical companies for target discovery and trial enrichment, and research collaborations with academic and scientific institutions. Distribution is exclusively direct enterprise sales—no self-service or marketplace channels—with customers including hospital systems, specialty clinics, payors/ACOs, self-insured corporations, academic researchers, and pharmaceutical partners. The company is HIPAA-compliant, GDPR-aligned, governed by Pennsylvania law, and operates with 1-10 employees from its headquarters at 5750 Centre Avenue, Suite 270, Pittsburgh.

Name

Ariel Precision Medicine

Legal name

ARIEL PRECISION MEDICINE, INC.

Website

https://arielmedicine.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Ariel Precision Medicine is a Pittsburgh-based clinical decision support company that uses its proprietary ADVANCE Data Engine to convert genomic and clinical data into peer-reviewed diagnostic reports for hospital systems and specialty clinics managing complex diseases, and is developing the Phase 2 ready CFTR-targeting therapeutic APM-176.

Ownership category

akta.pro rank

Product category

Precision Medicine Clinical Decision Support

NAICS

Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

Keywords

• Precision medicine
• Clinical decision support
• AI genomic analysis
• Targeted therapy
• CFTR therapeutics

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Clinical Diagnostic Reports: Ariel provides AI-powered, peer-reviewed clinical reports to clinicians that deliver deeper insights into complex diseases. This appears to be a subscription or per-report model where healthcare providers receive precision diagnostic insights for their most complex cases.
2. Therapeutic Development Partnership: Partnerships with pharmaceutical companies for target discovery, patient stratification, and clinical trial enrichment using proprietary data and analytics capabilities.
3. Research Collaboration Services: Collaboration with academic and scientific researchers for genetic analysis, population-level insights, complex condition interpretation, and expert interpretation of genetic datasets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Ariel Precision Medicine sells an AI-powered clinical decision support platform built around its proprietary ADVANCE Data Engine, which ingests multi-source clinical and genomic data to produce peer-reviewed, evidence-linked diagnostic and treatment reports for clinicians at hospital systems and specialty clinics. Complementing the platform, Ariel operates a therapeutic development pipeline led by APM-176, a Phase 2-ready oral small molecule targeting CFTR function for respiratory diseases, and pursues pharmaceutical partnerships for target discovery, patient stratification, and clinical trial enrichment.

Product overview

Ariel Precision Medicine operates as a platform-plus-modules architecture centered on its proprietary ADVANCE Data Engine. The core offering combines AI-powered clinical decision support (Clinician Reports) with a therapeutic development pipeline. ADVANCE processes multi-source data inputs—EHR/EMR, genomic profiles, lab results, imaging, and scientific literature—into peer-reviewed actionable reports delivered through web-based portals (Physician Portal, Medical Professional Portal, Patient Portal). The therapeutic pipeline centers on APM-176, an oral small molecule targeting CFTR function currently Phase 2 ready, with an intra-nasal formulation in preclinical development. The platform differentiates through non-LLM, equation-based machine learning designed to avoid hallucination risks.

Differentiator

Problem solved

Functional benefit

Products and services

• ADVANCE Data Engine

Quantifiable outcome

• Intervening earlier and more precisely drives measurable improvements in quality metrics and reduces complications for chronic pancreatitis, diabetes, and high-risk patients

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Caris Life Sciences: Molecular profiling and AI-driven precision medicine platform serving clinicians and biopharma. Comparable on combined clinical reporting + pharma partnership + therapeutic discovery model.
• Tempus Labs: AI-powered precision medicine platform that integrates genomic and clinical data to produce clinical reports for hospital systems and partners with pharma for drug discovery. Direct comparable on enterprise precision medicine CDx and pharma services.
• Flatiron Health: Oncology-focused health technology company connecting EHR data, genomics, and real-world evidence for clinical decision support and pharma research. Closely aligned on multi-source data integration and pharma services.

Emerging players

• Fabric Genomics: AI clinical decision support for rare and complex disease genomic interpretation. Comparable on AI-driven interpretation of complex genetic and clinical data for clinicians.
• Congenica: Clinical genomics interpretation platform for rare disease and hereditary conditions. Comparable on evidence-linked genomic reporting for clinical decision support in complex cases.
• Owkin: AI for clinical research and drug development that integrates multimodal patient data (including genomics) for pharma partners. Comparable on AI-driven precision medicine targeting complex diseases and pharma collaborations.
• PathAI: AI-driven pathology and precision diagnostics platform serving pharma and clinical customers. Comparable on AI clinical decision support combined with biopharma partnerships.

Broad incumbents

• Foundation Medicine: Genomic profiling and molecular information services supporting clinical decision making and pharma R&D. A Roche subsidiary operating at much larger scale in precision oncology with overlapping AI-driven reporting use cases.

Regional players

• BC Platforms: Clinical genomics and biobank data platform with primary presence in Europe serving pharma and clinical customers. Comparable on genomic data integration and pharma partnership model, though more Europe-focused.

Others

• DNAnexus: Cloud-based genomic data management and analytics platform serving clinical labs, hospitals, and pharma. Comparable as enabling infrastructure for multi-source genomic and clinical data workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ArielMedicine

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ariel Precision Medicine